前列腺癌放射治疗患者治疗前MRI的预后价值:系统综述与Meta分析
该系统综述与Meta分析纳入12项研究共2205例接受外照射放疗或近距离放疗的前列腺癌患者,评估治疗前MRI表现与生化复发、转移及死亡率的预后关联。结果显示前列腺外侵犯、精囊侵犯、肿瘤较大或体积大、受累六分区数及前列腺尖部受累是生化复发的显著预后因素(合并HR 1.50–4.47);盆腔淋巴结转移可显著预测癌症特异性死亡(HR 4.45 [95% CI, 1.30–15.23])。
要点
- 治疗前MRI示前列腺外侵犯、精囊侵犯、肿瘤大或体积大、受累六分区数多及前列腺尖部受累与生化复发显著相关。
- 盆腔淋巴结转移可显著预测癌症特异性死亡(HR 4.45 [95% CI, 1.30–15.23])。
- 前列腺外侵犯、肿瘤较大、体积较大、盆腔淋巴结转移及精囊侵犯是转移的显著危险因素(合并HR 1.12–11.96)。
诊断标准与关键数值
- 生化复发的显著预后因素包括前列腺外侵犯、精囊侵犯、肿瘤较大或体积大、受累六分区数及前列腺尖部受累,合并HR为1.50–4.47。
- 转移的显著危险因素包括前列腺外侵犯、肿瘤较大、肿瘤体积较大、盆腔淋巴结转移及精囊侵犯,合并HR为1.12–11.96。
- 盆腔淋巴结转移可显著预测癌症特异性死亡,HR为4.45(95% CI, 1.30–15.23)。
临床应用与阅片要点
- 阅片与报告治疗前MRI时,应关注并描述前列腺外侵犯、精囊侵犯、肿瘤大小或体积、受累六分区数、前列腺尖部受累及盆腔淋巴结转移等预后相关表现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. Despite a substantial increase in the use of MRI for pretreatment evaluation of prostate cancer, its prognostic value in patients undergoing radiation therapy (RT) is not well known. Therefore, the purpose of this study was to systematically review the literature and perform a meta-analysis on the prognostic value of pretreatment MRI in patients with prostate cancer who underwent external beam radiation therapy (EBRT) or brachytherapy. MATERIALS AND METHODS. PubMed and Embase databases were searched for studies published on or before March 13, 2019. We included studies that evaluated pretreatment MRI as a prognostic factor in prostate cancer regarding biochemical recurrence (BCR), metastatic failure, and overall or cancer-specific mortality. Effect sizes were measured in terms of the hazard ratio (HR) and were meta-analytically pooled using the random-effects model. The quality of the studies was independently evaluated using the Quality in Prognostic Studies tool. RESULTS. Twelve studies (2205 patients) were included. All studies assessed BCR; metastasis was evaluated in three studies, and mortality was evaluated in one study. Extraprostatic extension (EPE), seminal vesicle invasion (SVI), large tumor size or volume, number of sextants involved, and tumor involvement of prostatic apex were significant prognostic factors of BCR (pooled HRs = 1.50-4.47). EPE, larger tumor size, greater tumor volume, presence of metastatic pelvic lymph nodes (LNs), and presence of SVI were significant risk factors for metastasis (pooled HRs = 1.12-11.96). Pelvic LN metastasis was significantly predictive of cancer-specific mortality (HR = 4.45 [95% CI, 1.30-15.23]). CONCLUSION. Several pretreatment MRI findings were significant prognostic factors in patients with prostate cancer who underwent RT.
引用
- Woo S, Han S, Kim TH, et al. Prognostic Value of Pretreatment MRI in Patients With Prostate Cancer Treated With Radiation Therapy: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2019. PMID: 31799874. doi:10.2214/AJR.19.21836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。